106 results on '"Hurt, Aeron C"'
Search Results
2. Reducing Influenza Virus Transmission: The Potential Value of Antiviral Treatment.
- Author
-
Hayden FG, Asher J, Cowling BJ, Hurt AC, Ikematsu H, Kuhlbusch K, Lemenuel-Diot A, Du Z, Meyers LA, Piedra PA, Takazono T, Yen HL, and Monto AS
- Subjects
- Animals, Drug Resistance, Viral, Humans, Neuraminidase, Oseltamivir therapeutic use, Virus Replication, Antiviral Agents therapeutic use, Influenza, Human drug therapy, Influenza, Human prevention & control, Orthomyxoviridae
- Abstract
Prompt antiviral treatment has the potential to reduce influenza virus transmission to close contacts, but rigorous data on the magnitude of treatment effects on transmission are limited. Animal model data indicate that rapid reductions in viral replication after antiviral treatment reduce the risk of transmission. Observational and clinical trial data with oseltamivir and other neuraminidase inhibitors indicate that prompt treatment of household index patients seems to reduce the risk of illness in contacts, although the magnitude of the reported effects has varied widely across studies. In addition, the potential risk of transmitting drug-resistant variants exists with all approved classes of influenza antivirals. A controlled trial examining baloxavir treatment efficacy to reduce transmission, including the risk of transmitting virus with reduced baloxavir susceptibility, is currently in progress. If reduced transmission risk is confirmed, modeling studies indicate that early treatment could have major epidemiologic benefits in seasonal and pandemic influenza., (© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America.)
- Published
- 2022
- Full Text
- View/download PDF
3. Evaluating the fitness of PA/I38T-substituted influenza A viruses with reduced baloxavir susceptibility in a competitive mixtures ferret model.
- Author
-
Lee LY, Zhou J, Koszalka P, Frise R, Farrukee R, Baba K, Miah S, Shishido T, Galiano M, Hashimoto T, Omoto S, Uehara T, Mifsud EJ, Collinson N, Kuhlbusch K, Clinch B, Wildum S, Barclay WS, and Hurt AC
- Subjects
- Amino Acid Substitution, Animals, Female, Ferrets, Influenza A virus drug effects, Influenza A virus isolation & purification, Male, Orthomyxoviridae Infections virology, Antiviral Agents pharmacology, Dibenzothiepins pharmacology, Disease Models, Animal, Drug Resistance, Viral, Influenza A virus genetics, Morpholines pharmacology, Orthomyxoviridae Infections drug therapy, Pyridones pharmacology, Triazines pharmacology, Virus Replication
- Abstract
Baloxavir is approved in several countries for the treatment of uncomplicated influenza in otherwise-healthy and high-risk patients. Treatment-emergent viruses with reduced susceptibility to baloxavir have been detected in clinical trials, but the likelihood of widespread occurrence depends on replication capacity and onward transmission. We evaluated the fitness of A/H3N2 and A/H1N1pdm09 viruses with the polymerase acidic (PA) I38T-variant conferring reduced susceptibility to baloxavir relative to wild-type (WT) viruses, using a competitive mixture ferret model, recombinant viruses and patient-derived virus isolates. The A/H3N2 PA/I38T virus showed a reduction in within-host fitness but comparable between-host fitness to the WT virus, while the A/H1N1pdm09 PA/I38T virus had broadly similar within-host fitness but substantially lower between-host fitness. Although PA/I38T viruses replicate and transmit between ferrets, our data suggest that viruses with this amino acid substitution have lower fitness relative to WT and this relative fitness cost was greater in A/H1N1pdm09 viruses than in A/H3N2 viruses., Competing Interests: I have read the journal’s policy and the authors of this manuscript have the following competing interests: • Keiko Baba, Takashi Hashimoto, Shinya Omoto, Takao Shishido and Takeki Uehara are employees of Shionogi & Co. • Klaus Kuhlbusch, Steffen Wildum and Aeron C Hurt are employees of F. Hoffmann-La Roche. • Neil Collinson and Barry Clinch are employees of Roche Products Ltd. • Wendy Barclay has received honoraria from Roche, Sanofi Pasteur and Seqirus. • Leo YY Lee has received honoraria from Roche. • Paulina Koszalka, Jie Zhou, Rubaiyea Farrukee, Rebecca Frise, Edin Mifsud, Monica Galiano and Shahjahan Miah have nothing to disclose.
- Published
- 2021
- Full Text
- View/download PDF
4. Understanding the Impact of Resistance to Influenza Antivirals.
- Author
-
Holmes EC, Hurt AC, Dobbie Z, Clinch B, Oxford JS, and Piedra PA
- Subjects
- Drug Resistance, Viral, Humans, Antiviral Agents pharmacology, Antiviral Agents therapeutic use, Influenza, Human drug therapy
- Abstract
Influenza poses a significant burden on society and health care systems. Although antivirals are an integral tool in effective influenza management, the potential for the emergence of antiviral-resistant viruses can lead to uncertainty and hesitation among front-line prescribers and policy makers. Here, we provide an overview of influenza antiviral resistance in context, exploring the key concepts underlying its development and clinical impact. Due to the acute nature of influenza in immunocompetent patients, resistant viruses that develop during antiviral treatment of a single patient ("treatment-emergent resistance") are usually cleared in a relatively short time, with no impact on future antiviral efficacy. In addition, although available data are limited by small numbers of patients, they show that antiviral treatment still provides clinical benefit to the patient within whom resistance emerges. In contrast, the sustained community transmission of resistant variants in the absence of treatment ("acquired resistance") is of greater concern and can potentially render front-line antivirals ineffective. Importantly, however, resistant viruses are usually associated with reduced fitness such that their widespread transmission is relatively rare. Influenza antivirals are an essential part of effective influenza management due to their ability to reduce the risk of complications and death in infected patients. Although antiviral resistance should be taken seriously and requires continuous careful monitoring, it is not comparable to antibiotic resistance in bacteria, which can become permanent and widespread, with far-reaching medical consequences. The benefits of antiviral treatment far outweigh concerns of potential resistance, which in the vast majority of cases does not have a significant clinical impact., (Copyright © 2021 American Society for Microbiology.)
- Published
- 2021
- Full Text
- View/download PDF
5. Viral burden, inflammatory milieu and CD8 + T-cell responses to influenza virus in a second-generation thiazolide (RM-5061) and oseltamivir combination therapy study.
- Author
-
Nüssing S, Mifsud E, Hensen L, Koutsakos M, Wang Z, Kedzierski L, Mercuri F, Rossignol JF, Hurt AC, and Kedzierska K
- Subjects
- Animals, Bronchoalveolar Lavage Fluid immunology, CD8-Positive T-Lymphocytes pathology, Cytokines metabolism, Inflammation, Influenza A virus drug effects, Killer Cells, Natural pathology, Lung drug effects, Lung immunology, Mice, Neutrophils pathology, Orthomyxoviridae Infections virology, Weight Loss drug effects, Antiviral Agents therapeutic use, Orthomyxoviridae Infections drug therapy, Oseltamivir therapeutic use, Thiazoles therapeutic use, Viral Load drug effects
- Abstract
Background: Influenza viruses cause significant morbidity and mortality, especially in young children, elderly, pregnant women and individuals with co-morbidities. Patients with severe influenza disease are typically treated with one neuraminidase inhibitor, oseltamivir or zanamivir. These antivirals need to be taken early to be most effective and often lead to the emergence of drug resistance and/or decreased drug susceptibility. Combining oseltamivir with another antiviral with an alternative mode of action has the potential to improve clinical effectiveness and reduce drug resistance., Methods: In this study, we utilized a host-targeting molecule RM-5061, a second-generation thiazolide, in combination with oseltamivir to determine whether these compounds could reduce viral burden and understand their effects on the immune response to influenza virus infection in mice, compared with either monotherapy or placebo., Results: The combination of RM-5061 and OST administered for 5 days after influenza infection reduced viral burden at day 5 post-infection, when compared to placebo and RM-5061 monotherapy, but was not significantly different from oseltamivir monotherapy. The inflammatory cytokine milieu was also reduced in animals which received a combination therapy when compared to RM-5061 and placebo-treated animals. Antiviral treatment in all groups led to a reduction in CD8
+ T-cell responses in the BAL when compared to placebo., Conclusions: To our knowledge, this is the first time a combination of a host-targeting compound, RM-5061, and neuraminidase inhibitor, OST, has been tested in vivo. This antiviral combination was safe in mice and led to reduced inflammatory responses following viral infection when compared to untreated animals., (© 2020 The Authors. Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd.)- Published
- 2020
- Full Text
- View/download PDF
6. Host-targeted nitazoxanide has a high barrier to resistance but does not reduce the emergence or proliferation of oseltamivir-resistant influenza viruses in vitro or in vivo when used in combination with oseltamivir.
- Author
-
Tilmanis D, Koszalka P, Barr IG, Rossignol JF, Mifsud E, and Hurt AC
- Subjects
- Animals, Antiviral Agents pharmacology, Cell Proliferation drug effects, Dogs, Drug Therapy, Combination, Female, Ferrets, Influenza A Virus, H1N1 Subtype genetics, Madin Darby Canine Kidney Cells, Male, Nitro Compounds pharmacology, Orthomyxoviridae Infections drug therapy, Orthomyxoviridae Infections virology, Oseltamivir pharmacology, Thiazoles pharmacology, Antiviral Agents therapeutic use, Drug Resistance, Viral, Influenza A Virus, H1N1 Subtype drug effects, Nitro Compounds therapeutic use, Oseltamivir therapeutic use, Thiazoles therapeutic use
- Abstract
A major limitation of the currently available influenza antivirals is the potential development of drug resistance. The adamantanes, neuraminidase inhibitors, and more recently polymerase inhibitors, have all been associated with the emergence of viral resistance in preclinical, clinical studies or in clinical use. As a result, host-targeted drugs that act on cellular proteins or functions have become an attractive option for influenza treatment as they are less likely to select for resistance. Nitazoxanide (NTZ) is a host-targeted antiviral that is currently in Phase III clinical trials for the treatment of influenza. In this study, we investigated the propensity for circulating influenza viruses to develop resistance to nitazoxanide in vitro by serially passaging viruses under selective pressure. Phenotypic and genotypic analysis of viruses passaged ten times in the presence of up to 20 μM tizoxanide (TIZ; the active metabolite of nitazoxanide) showed that none had a significant change in TIZ susceptibility, and amino acid substitutions arising that were unique to TIZ passaged viruses, did not alter TIZ susceptibility. Combination therapy, particularly utilising drugs with different mechanisms of action, is another option for combatting antiviral resistance, and while combination therapy has been shown to improve antiviral effects, the effect of reducing the emergence and selection of drug-resistant virus has been less widely investigated. Here we examined the use of TIZ in combination with oseltamivir, both in vitro and using the ferret model for influenza infection and found that the combination of the two drugs did not provide significant benefit in reducing the emergence or selection of oseltamivir-resistant virus. These in vitro findings suggest that clinical use of NTZ may be significantly less likely to select for resistance in circulating influenza viruses compared to virus-targeted antivirals, and although the combination of NTZ with oseltamivir did not reduce the emergence of oseltamivir-resistant virus in vitro or in vivo, combination therapy with NTZ and other newer classes of influenza antiviral drugs should be considered due to NTZ's higher host-based barrier to resistance., (Copyright © 2020 Elsevier B.V. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
7. A rapid pyrosequencing assay for the molecular detection of influenza viruses with reduced baloxavir susceptibility due to PA/I38X amino acid substitutions.
- Author
-
Koszalka P, Farrukee R, Mifsud E, Vijaykrishna D, and Hurt AC
- Subjects
- Genotype, Humans, Orthomyxoviridae classification, Orthomyxoviridae drug effects, Reproducibility of Results, Viral Proteins genetics, Amino Acid Substitution genetics, Antiviral Agents pharmacology, Dibenzothiepins pharmacology, Drug Resistance, Viral genetics, High-Throughput Nucleotide Sequencing methods, Morpholines pharmacology, Orthomyxoviridae genetics, Pyridones pharmacology, Triazines pharmacology
- Abstract
Baloxavir marboxil is a novel endonuclease inhibitor licensed for treatment of otherwise healthy or high-risk individuals infected with influenza. Viruses with reduced baloxavir susceptibility due to amino acid substitutions at residue 38 of the PA have been detected in some individuals following treatment. Here, we describe a genotypic pyrosequencing method that can be used to rapidly screen circulating influenza A and B viruses for substitutions in the PA/I38 codon and to quantify mixed viral populations. This method is suitable for surveillance of baloxavir susceptibility and to analyse samples from hospitalised patients undergoing baloxavir treatment to aid in clinical decision making., (© 2020 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd.)
- Published
- 2020
- Full Text
- View/download PDF
8. Baloxavir treatment of ferrets infected with influenza A(H1N1)pdm09 virus reduces onward transmission.
- Author
-
Lee LYY, Zhou J, Frise R, Goldhill DH, Koszalka P, Mifsud EJ, Baba K, Noda T, Ando Y, Sato K, Yuki AI, Shishido T, Uehara T, Wildum S, Zwanziger E, Collinson N, Kuhlbusch K, Clinch B, Hurt AC, and Barclay WS
- Subjects
- Animals, Dibenzothiepins, Female, Ferrets, Morpholines, Orthomyxoviridae Infections transmission, Orthomyxoviridae Infections virology, Pyridones, Antiviral Agents pharmacology, Influenza A Virus, H1N1 Subtype drug effects, Neuraminidase antagonists & inhibitors, Orthomyxoviridae Infections drug therapy, Oxazines pharmacology, Pyridines pharmacology, Thiepins pharmacology, Triazines pharmacology, Virus Replication drug effects, Virus Shedding drug effects
- Abstract
Influenza viruses cause seasonal outbreaks and pose a continuous pandemic threat. Although vaccines are available for influenza control, their efficacy varies each season and a vaccine for a novel pandemic virus manufactured using current technology will not be available fast enough to mitigate the effect of the first pandemic wave. Antivirals can be effective against many different influenza viruses but have not thus far been used extensively for outbreak control. Baloxavir, a recently licensed antiviral drug that targets the influenza virus endonuclease, has been shown to reduce virus shedding more effectively than oseltamivir, a widely used neuraminidase inhibitor drug. Thus it is possible that treatment with baloxavir might also interrupt onward virus transmission. To test this, we utilized the ferret model, which is the most commonly used animal model to study influenza virus transmission. We established a subcutaneous baloxavir administration method in ferrets which achieved similar pharmacokinetics to the approved human oral dose. Transmission studies were then conducted in two different locations with different experimental setups to compare the onward transmission of A(H1N1)pdm09 virus from infected ferrets treated with baloxavir, oseltamivir or placebo to naïve sentinel ferrets exposed either indirectly in adjacent cages or directly by co-housing. We found that baloxavir treatment reduced infectious viral shedding in the upper respiratory tract of ferrets compared to placebo, and reduced the frequency of transmission amongst sentinels in both experimental setups, even when treatment was delayed until 2 days post-infection. In contrast, oseltamivir treatment did not substantially affect viral shedding or transmission compared to placebo. We did not detect the emergence of baloxavir-resistant variants in treated animals or in untreated sentinels. Our results support the concept that antivirals which decrease viral shedding could also reduce influenza transmission in the community., Competing Interests: I have read the journal's policy and the authors of this manuscript have the following competing interests: Leo Yi Yang Lee, Jie Zhou, Rebecca Frise, Daniel H. Goldhill, Paulina Koszalka and Edin J. Mifsud have nothing to declare. Kaoru Baba, Takahiro Noda, Yoshinori Ando, Kenji Sato, Aoe-Ishikawa Yuki, Takao Shishido and Takeki Uehara are employees of Shionogi & Co. Ltd. Steffen Wildum, Elke Zwanziger, Neil Collinson, Klaus Kuhlbusch, Barry Clinch and Aeron C. Hurt are employees of F. Hoffmann La Roche Ltd. Wendy S. Barclay has received honoraria from Roche, Sanofi Pasteur and Seqirus.
- Published
- 2020
- Full Text
- View/download PDF
9. Prophylaxis of ferrets with nitazoxanide and oseltamivir combinations is more effective at reducing the impact of influenza a virus infection compared to oseltamivir monotherapy.
- Author
-
Mifsud EJ, Tilmanis D, Oh DY, Ming-Kay Tai C, Rossignol JF, and Hurt AC
- Subjects
- Administration, Oral, Animals, Chemoprevention, Dogs, Drug Combinations, Drug Resistance, Viral, Female, Ferrets virology, Influenza A Virus, H1N1 Subtype drug effects, Lung virology, Madin Darby Canine Kidney Cells, Male, Nitro Compounds, Virus Shedding drug effects, Antiviral Agents administration & dosage, Orthomyxoviridae Infections prevention & control, Oseltamivir administration & dosage, Thiazoles administration & dosage
- Abstract
Combination therapy is an alternative approach to reduce viral shedding and improve clinical outcomes following influenza virus infections. In this study we used oseltamivir (OST), a neuraminidase inhibitor and nitazoxanide (NTZ), a host directed drug, and found in vitro that the combination of these two antivirals have a synergistic relationship. Using the ferret model of (A/Perth/265/2009, (H1N1)pdm09), virus infections, we found that the combination of NTZ and OST was more effective than either NTZ or OST independently in preventing infection and reducing duration of viral shedding. However, these benefits were only seen if treatment was administered prophylactically, as opposed to therapeutically. We also found that if prophylactically treated ferrets that had detectable virus in the upper respiratory tract, no virus was detected in the lower respiratory tract. This benefit was not observed with NTZ or OST alone. The combination of NTZ and OST enhances the antiviral effect of OST, which is the standard of care in most settings., (Copyright © 2020. Published by Elsevier B.V.)
- Published
- 2020
- Full Text
- View/download PDF
10. Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2017-2018.
- Author
-
Takashita E, Daniels RS, Fujisaki S, Gregory V, Gubareva LV, Huang W, Hurt AC, Lackenby A, Nguyen HT, Pereyaslov D, Roe M, Samaan M, Subbarao K, Tse H, Wang D, Yen HL, Zhang W, and Meijer A
- Subjects
- Amino Acid Substitution, Global Health, Humans, Influenza A Virus, H1N1 Subtype genetics, Influenza B virus genetics, Influenza, Human epidemiology, Influenza, Human virology, Inhibitory Concentration 50, Mutation, Oseltamivir pharmacology, Antiviral Agents pharmacology, Dibenzothiepins pharmacology, Drug Resistance, Viral genetics, Enzyme Inhibitors pharmacology, Influenza A Virus, H1N1 Subtype drug effects, Influenza B virus drug effects, Morpholines pharmacology, Pyridones pharmacology, Triazines pharmacology
- Abstract
The global analysis of neuraminidase inhibitor (NAI) susceptibility of influenza viruses has been conducted since the 2012-13 period. In 2018 a novel cap-dependent endonuclease inhibitor, baloxavir, that targets polymerase acidic subunit (PA) was approved for the treatment of influenza virus infection in Japan and the United States. For this annual report, the susceptibilities of influenza viruses to NAIs and baloxavir were analyzed. A total of 15409 viruses, collected by World Health Organization (WHO) recognized National Influenza Centers and other laboratories between May 2017 and May 2018, were assessed for phenotypic NAI susceptibility by five WHO Collaborating Centers (CCs). The 50% inhibitory concentration (IC
50 ) was determined for oseltamivir, zanamivir, peramivir and laninamivir. Reduced inhibition (RI) or highly reduced inhibition (HRI) by one or more NAIs was exhibited by 0.8% of viruses tested (n = 122). The frequency of viruses with RI or HRI has remained low since this global analysis began (2012-13: 0.6%; 2013-14: 1.9%; 2014-15: 0.5%; 2015-16: 0.8%; 2016-17: 0.2%). PA gene sequence data, available from public databases (n = 13523), were screened for amino acid substitutions associated with reduced susceptibility to baloxavir (PA E23G/K/R, PA A36V, PA A37T, PA I38F/M/T/L, PA E119D, PA E199G): 11 (0.08%) viruses possessed such substitutions. Five of them were included in phenotypic baloxavir susceptibility analysis by two WHO CCs and IC50 values were determined. The PA variant viruses showed 6-17-fold reduced susceptibility to baloxavir. Overall, in the 2017-18 period the frequency of circulating influenza viruses with reduced susceptibility to NAIs or baloxavir was low, but continued monitoring is important., Competing Interests: Declaration of competing interest None., (Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.)- Published
- 2020
- Full Text
- View/download PDF
11. Treatment-Emergent Influenza Variant Viruses With Reduced Baloxavir Susceptibility: Impact on Clinical and Virologic Outcomes in Uncomplicated Influenza.
- Author
-
Uehara T, Hayden FG, Kawaguchi K, Omoto S, Hurt AC, De Jong MD, Hirotsu N, Sugaya N, Lee N, Baba K, Shishido T, Tsuchiya K, Portsmouth S, and Kida H
- Subjects
- Adolescent, Adult, Amino Acid Substitution, Antiviral Agents pharmacology, Child, Dibenzothiepins, Double-Blind Method, Female, Humans, Influenza, Human virology, Male, Middle Aged, Morpholines, Oseltamivir therapeutic use, Oxazines pharmacology, Pyridines pharmacology, Pyridones, Risk Factors, Thiepins pharmacology, Treatment Outcome, Triazines pharmacology, Viral Load drug effects, Young Adult, Antiviral Agents therapeutic use, Drug Resistance, Viral drug effects, Influenza A Virus, H3N2 Subtype drug effects, Influenza A Virus, H3N2 Subtype genetics, Influenza, Human drug therapy, Oxazines therapeutic use, Pyridines therapeutic use, Thiepins therapeutic use, Triazines therapeutic use
- Abstract
Background: Single-dose baloxavir rapidly reduces influenza virus titers and symptoms in patients with uncomplicated influenza, but viruses with reduced in vitro susceptibility due to amino acid substitutions at position 38 of polymerase acidic protein (PA/I38X) sometimes emerge., Methods: We evaluated the kinetics, risk factors, and effects on clinical and virologic outcomes of emergence of PA/I38X-substituted viruses., Results: Viruses containing PA/I38X substitutions were identified 3-9 days after baloxavir treatment in 9.7% (36/370) of patients, of whom 85.3% had transient virus titer rises. Median time to sustained cessation of infectious virus detection was 192, 48, and 96 hours in the baloxavir recipients with PA/I38X-substituted viruses, without PA/I38X-substituted viruses, and placebo recipients, respectively. The corresponding median times to alleviation of symptoms were 63.1, 51.0, and 80.2 hours, respectively. After day 5, symptom increases occurred in 11.5%, 8.0%, and 13.0%, respectively, and in 8.9% of oseltamivir recipients. Variant virus emergence was associated with lower baseline neutralizing antibody titers., Conclusions: The emergence of viruses with PA/I38X substitutions following baloxavir treatment was associated with transient rises in infectious virus titers, prolongation of virus detectability, initial delay in symptom alleviation, and uncommonly with symptom rebound. The potential transmissibility of PA/I38X-substituted viruses requires careful study., Clinical Trial Registration: NCT02954354., (© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.)
- Published
- 2020
- Full Text
- View/download PDF
12. Assessing the susceptibility of highly pathogenic avian influenza H5N1 viruses to oseltamivir using embryonated chicken eggs.
- Author
-
Tare DS, Kode SS, Hurt AC, and Pawar SD
- Subjects
- Animals, Chickens, Drug Resistance, Viral genetics, Eggs virology, Enzyme Inhibitors pharmacology, India epidemiology, Influenza A Virus, H5N1 Subtype pathogenicity, Influenza in Birds epidemiology, Influenza in Birds virology, Antiviral Agents pharmacology, Influenza A Virus, H5N1 Subtype drug effects, Influenza in Birds drug therapy, Oseltamivir pharmacology
- Abstract
Background & Objectives: The susceptibility of influenza viruses to neuraminidase inhibitors (NAIs) is studied using enzyme-based assays, sequence analysis and in vitro and in vivo studies. Oseltamivir carboxylate (OC) is the active prodrug of the NAI oseltamivir. There is lack of information on the use of embryonated chicken eggs for studying susceptibility of highly pathogenic avian influenza (HPAI) H5N1 viruses to antiviral drugs. The aim of the present study was to assess the use of 10 day old embryonated chicken eggs for studying antiviral susceptibility of HPAI H5N1 viruses., Methods: Two HPAI H5N1 viruses isolated from India were used in the study. Fluorescence-based NAI assay was performed to determine antiviral susceptibility of these viruses. In ovo antiviral assays were carried out using 10 day old embryonated chicken eggs. The virus dilutions were incubated with 14 μg/ml of OC and inoculated in the allantoic cavity. In the eggs, 50 per cent egg infectious dose (EID
50 ) titres as well as mortality were quantitated., Results: The two viruses used were susceptible to OC in the NAI assay. It was found that there was a significant drop in EID50 titres; however, no significant protection from mortality after OC treatment was observed., Interpretation & Conclusions: By measuring viral titres, the egg model was suitable to study the susceptibility of HPAI viruses to antiviral drugs along with NAI assay. The present study highlights the use of eggs as a model to study susceptibility of HPAI viruses to OC., Competing Interests: None- Published
- 2019
- Full Text
- View/download PDF
13. Antivirals targeting the polymerase complex of influenza viruses.
- Author
-
Mifsud EJ, Hayden FG, and Hurt AC
- Subjects
- Amides pharmacology, Dibenzothiepins, Drug Combinations, Drug Resistance, Viral drug effects, Enzyme Inhibitors pharmacology, Humans, Influenza A virus drug effects, Influenza B virus drug effects, Morpholines, Oseltamivir pharmacology, Oxazines, Pyrazines pharmacology, Pyridines, Pyridones, Serine Endopeptidases pharmacology, Thiepins, Triazines, Antiviral Agents pharmacology, Antiviral Agents therapeutic use, DNA-Directed RNA Polymerases drug effects, Neuraminidase antagonists & inhibitors, Orthomyxoviridae drug effects
- Abstract
Current influenza antivirals have limitations with regard to their effectiveness and the potential emergence of resistance. Encouragingly, several new compounds which inhibit the polymerase of influenza viruses have recently been shown to have enhanced pre-clinical and clinical effectiveness compared to the neuraminidase inhibitors, the mainstay of influenza antiviral therapy over the last two decades. In this review we focus on four compounds which inhibit polymerase function, baloxavir marboxil, favipiravir, pimodivir and AL-794 and discuss their clinical and virological effectiveness, their propensity to select for resistance and their potential for future combination therapy with the most commonly used neuraminidase inhibitor, oseltamivir., (Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
14. A novel I117T substitution in neuraminidase of highly pathogenic avian influenza H5N1 virus conferring reduced susceptibility to oseltamivir and zanamivir.
- Author
-
Kode SS, Pawar SD, Tare DS, Keng SS, Hurt AC, and Mullick J
- Subjects
- Amino Acid Substitution, Animals, Chickens, Drug Resistance, Viral, India, Influenza A Virus, H5N1 Subtype genetics, Inhibitory Concentration 50, Mutation, Missense, Zygote, Antiviral Agents pharmacology, Influenza A Virus, H5N1 Subtype drug effects, Neuraminidase genetics, Oseltamivir pharmacology, Viral Proteins genetics, Zanamivir pharmacology
- Abstract
Occurrence of avian influenza (AI) with Neuraminidase (NA) mutations which confer reduced neuraminidase inhibitor (NAI) susceptibility has remained a cause of concern. The susceptibility to NAIs of 67 highly pathogenic avian influenza H5N1 viruses isolated during 2006-2012 in India was tested in phenotypic fluorescence-based NA inhibition assay, sequence analysis and in ovo. One isolate showed a novel NA I117T amino acid substitution (N2 numbering) and eight isolates showed previously known NAI-resistance marker mutations (I117V, E119D, N294S, total 9/67). The overall incidence of resistant variants was 13.4%. The novel I117T substitution reduced oseltamivir susceptibility by 18.6-fold and zanamivir susceptibility by 11.8-fold, compared to the wild type AI H5N1virus, thus showed cross-resistance to both oseltamivir and zanamivir in NA inhibition assays. However, the other two isolates with I117V substitution were sensitive to both the NAIs. In addition, the comparison of growth of the I117T and I117V variants in presence of NAI's in the in ovo assays exhibited difference in growth levels. The present study reports the natural occurrence of a novel I117T mutation in AI H5N1 virus conferring cross-resistance to oseltamivir and zanamivir highlighting the urgent need of antiviral surveillance of AI viruses., (Copyright © 2019 Elsevier B.V. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
15. Baloxavir marboxil susceptibility of influenza viruses from the Asia-Pacific, 2012-2018.
- Author
-
Koszalka P, Tilmanis D, Roe M, Vijaykrishna D, and Hurt AC
- Subjects
- Dibenzothiepins, Drug Resistance, Viral, Enzyme Inhibitors pharmacology, Influenza A Virus, H1N1 Subtype drug effects, Influenza A Virus, H1N1 Subtype enzymology, Influenza A Virus, H3N2 Subtype drug effects, Influenza A Virus, H3N2 Subtype enzymology, Influenza B virus drug effects, Influenza B virus enzymology, Inhibitory Concentration 50, Microbial Sensitivity Tests, Morpholines, Orthomyxoviridae enzymology, Pyridones, Antiviral Agents pharmacology, Orthomyxoviridae drug effects, Oxazines pharmacology, Pyridines pharmacology, RNA-Dependent RNA Polymerase antagonists & inhibitors, Thiepins pharmacology, Triazines pharmacology, Viral Proteins antagonists & inhibitors
- Abstract
Baloxavir Marboxil (BXM) is an influenza polymerase inhibitor antiviral that binds to the endonuclease region in the PA subunit of influenza A and B viruses. To establish the baseline susceptibility of viruses circulating prior to licensure of BXM and to monitor for susceptibility post-BXM use, a cell culture-based focus reduction assay was developed to determine the susceptibility of 286 circulating seasonal influenza viruses, A(H1N1)pdm09, A(H3N2), B (Yamagata/Victoria) lineage viruses, including neuraminidase inhibitor (NAI) resistant viruses, to Baloxavir Acid (BXA), the active metabolic form of BXM. BXA was effective against all influenza subtypes tested with mean EC
50 values (minimum-maximum) of 0.7 ± 0.5 nM (0.1-2.1 nM), 1.2 ± 0.6 nM (0.1-2.4), 7.2 ± 3.5 nM (0.7-14.8), and 5.8 ± 4.5 nM (1.8-15.5) obtained for A(H1N1)pdm09, A(H3N2), B(Victoria lineage), and B(Yamagata lineage) influenza viruses, respectively. Using reverse genetics, amino acid substitutions known to alter BXA susceptibility were introduced into the PA protein resulting in EC50 fold change increases that ranged from 2 to 65. Our study demonstrates that currently circulating viruses are susceptible to BXA and that the newly developed focus reduction assay is well suited to susceptibility monitoring in reference laboratories., (Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.)- Published
- 2019
- Full Text
- View/download PDF
16. Neuraminidase inhibitor resistance in influenza: a clinical perspective.
- Author
-
Lee N and Hurt AC
- Subjects
- Humans, Influenza A virus drug effects, Influenza B virus drug effects, Viral Proteins antagonists & inhibitors, Antiviral Agents pharmacology, Antiviral Agents therapeutic use, Drug Resistance, Viral, Enzyme Inhibitors pharmacology, Enzyme Inhibitors therapeutic use, Influenza, Human drug therapy, Neuraminidase antagonists & inhibitors
- Abstract
Purpose of Review: Neuraminidase inhibitors (NAIs), including oseltamivir, zanamivir, and peramivir, is the main class of antiviral available for clinical use. As such, development of resistance toward these agents is of great clinical and public health concern., Recent Findings: At present, NAI resistance remains uncommon among the circulating viruses (oseltamivir <3.5%, zanamivir <1%). Resistance risk is slightly higher in A(H1N1) than A(H3N2) and B viruses. Resistance may emerge during drug exposure, particularly among young children (<5 years), the immunocompromised, and individuals receiving prophylactic regimens. H275Y A(H1N1) variant, showing high-level oseltamivir resistance, is capable of causing outbreaks. R294K A(H7N9) variant shows reduced inhibition across NAIs. Multi-NAI resistance has been reported in the immunocompromised., Summary: These findings highlight the importance of continuous surveillance, and assessment of viral fitness and transmissibility of resistant virus strains. Detection can be challenging, especially in a mix of resistant and wild-type viruses. Recent advances in molecular techniques (e.g. targeted mutation PCR, iART, ddPCR, pyrosequencing, next-generation sequencing) have improved detection and our understanding of viral dynamics. Treatment options available for oseltamivir-resistant viruses are limited, and susceptibility testing of other NAIs may be required, but non-NAI antivirals (e.g. polymerase inhibitors) that are active against these resistant viruses are in late-stage clinical development.
- Published
- 2018
- Full Text
- View/download PDF
17. Animal models used to assess influenza antivirals.
- Author
-
Mifsud EJ, Tai CM, and Hurt AC
- Subjects
- Animals, Antiviral Agents pharmacology, Cricetinae, Disease Susceptibility, Ferrets, Guinea Pigs, Humans, Influenza, Human drug therapy, Influenza, Human transmission, Influenza, Human virology, Mesocricetus, Mice, Orthomyxoviridae Infections transmission, Orthomyxoviridae Infections virology, Primates, Sigmodontinae, Antiviral Agents administration & dosage, Disease Models, Animal, Orthomyxoviridae Infections drug therapy
- Abstract
Introduction: Influenza continues to be a major public health concern. Antivirals play an important role in limiting the burden of disease and preventing infection and/or transmission. The developments of such agents are heavily dependent on pre-clinical evaluation where animal models are used to answer questions that cannot be easily addressed in human clinical trials. There are numerous animal models available to study the potential benefits of influenza antivirals but each animal model has its own pros and cons. Areas covered: In this review, the authors describe the advantages and disadvantages of using mice, ferrets, guinea pigs, cotton rats, golden hamsters and non-human primates to evaluate influenza therapeutics. Expert opinion: Animals used for evaluating influenza therapeutics differ in their susceptibility to influenza virus infection, their ability to display clinical signs of illness following viral infection and in their practical requirements such as housing. Therefore, defining the scientific question being asked and the data output required will assist in selecting the most appropriate animal model.
- Published
- 2018
- Full Text
- View/download PDF
18. Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents.
- Author
-
Hayden FG, Sugaya N, Hirotsu N, Lee N, de Jong MD, Hurt AC, Ishida T, Sekino H, Yamada K, Portsmouth S, Kawaguchi K, Shishido T, Arai M, Tsuchiya K, Uehara T, and Watanabe A
- Subjects
- Adolescent, Adult, Antiviral Agents adverse effects, Antiviral Agents therapeutic use, Child, Dibenzothiepins, Double-Blind Method, Endonucleases antagonists & inhibitors, Female, Humans, Influenza, Human virology, Intention to Treat Analysis, Kaplan-Meier Estimate, Male, Middle Aged, Morpholines, Oxazines adverse effects, Pyridines adverse effects, Pyridones, Thiepins adverse effects, Triazines adverse effects, Viral Load, Virus Replication drug effects, Young Adult, Antiviral Agents administration & dosage, Influenza, Human drug therapy, Oseltamivir therapeutic use, Oxazines administration & dosage, Pyridines administration & dosage, Thiepins administration & dosage, Triazines administration & dosage
- Abstract
Background: Baloxavir marboxil is a selective inhibitor of influenza cap-dependent endonuclease. It has shown therapeutic activity in preclinical models of influenza A and B virus infections, including strains resistant to current antiviral agents., Methods: We conducted two randomized, double-blind, controlled trials involving otherwise healthy outpatients with acute uncomplicated influenza. After a dose-ranging (10 to 40 mg) placebo-controlled trial, we undertook a placebo- and oseltamivir-controlled trial of single, weight-based doses of baloxavir (40 or 80 mg) in patients 12 to 64 years of age during the 2016-2017 season. The dose of oseltamivir was 75 mg twice daily for 5 days. The primary efficacy end point was the time to alleviation of influenza symptoms in the intention-to-treat infected population., Results: In the phase 2 trial, the median time to alleviation of influenza symptoms was 23.4 to 28.2 hours shorter in the baloxavir groups than in the placebo group (P<0.05). In the phase 3 trial, the intention-to-treat infected population included 1064 patients; 84.8 to 88.1% of patients in each group had influenza A(H3N2) infection. The median time to alleviation of symptoms was 53.7 hours (95% confidence interval [CI], 49.5 to 58.5) with baloxavir, as compared with 80.2 hours (95% CI, 72.6 to 87.1) with placebo (P<0.001). The time to alleviation of symptoms was similar with baloxavir and oseltamivir. Baloxavir was associated with greater reductions in viral load 1 day after initiation of the regimen than placebo or oseltamivir. Adverse events were reported in 20.7% of baloxavir recipients, 24.6% of placebo recipients, and 24.8% of oseltamivir recipients. The emergence of polymerase acidic protein variants with I38T/M/F substitutions conferring reduced susceptibility to baloxavir occurred in 2.2% and 9.7% of baloxavir recipients in the phase 2 trial and phase 3 trial, respectively., Conclusions: Single-dose baloxavir was without evident safety concerns, was superior to placebo in alleviating influenza symptoms, and was superior to both oseltamivir and placebo in reducing the viral load 1 day after initiation of the trial regimen in patients with uncomplicated influenza. Evidence for the development of decreased susceptibility to baloxavir after treatment was also observed. (Funded by Shionogi; JapicCTI number, 153090, and CAPSTONE-1 ClinicalTrials.gov number, NCT02954354 .).
- Published
- 2018
- Full Text
- View/download PDF
19. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors and status of novel antivirals, 2016-2017.
- Author
-
Lackenby A, Besselaar TG, Daniels RS, Fry A, Gregory V, Gubareva LV, Huang W, Hurt AC, Leang SK, Lee RTC, Lo J, Lollis L, Maurer-Stroh S, Odagiri T, Pereyaslov D, Takashita E, Wang D, Zhang W, and Meijer A
- Subjects
- Amino Acid Substitution, Global Health, Humans, Influenza, Human epidemiology, Inhibitory Concentration 50, Microbial Sensitivity Tests, Mutation, Missense, Neuraminidase genetics, Orthomyxoviridae enzymology, Orthomyxoviridae isolation & purification, Prevalence, Sequence Analysis, DNA, Antiviral Agents pharmacology, Drug Resistance, Viral, Enzyme Inhibitors pharmacology, Influenza, Human virology, Neuraminidase antagonists & inhibitors, Orthomyxoviridae drug effects
- Abstract
A total of 13672 viruses, collected by World Health Organization recognised National Influenza Centres between May 2016 and May 2017, were assessed for neuraminidase inhibitor susceptibility by four WHO Collaborating Centres for Reference and Research on Influenza and one WHO Collaborating Centre for the Surveillance Epidemiology and Control of Influenza. The 50% inhibitory concentration (IC
50 ) was determined for oseltamivir and zanamivir for all viruses, and for peramivir and laninamivir in a subset (n = 8457). Of the viruses tested, 94% were obtained from the Western Pacific, Americas and European WHO regions, while limited viruses were available from the Eastern Mediterranean, African and South East Asian regions. Reduced inhibition (RI) by one or more neuraminidase inhibitor was exhibited by 0.2% of viruses tested (n = 32). The frequency of viruses with RI has remained low since this global analysis began (2015/16: 0.8%, 2014/15: 0.5%; 2013/14: 1.9%; 2012/13: 0.6%) but 2016/17 has the lowest frequency observed to date. Analysis of 13581 neuraminidase sequences retrieved from public databases, of which 5243 sequences were from viruses not included in the phenotypic analyses, identified 58 further viruses (29 without phenotypic analyses) with amino acid substitutions associated with RI by at least one neuraminidase inhibitor. Bringing the total proportion to 0.5% (90/18915). This 2016/17 analysis demonstrates that neuraminidase inhibitors remain suitable for treatment and prophylaxis of influenza virus infections, but continued monitoring is important. An expansion of surveillance testing is paramount since several novel influenza antivirals are in late stage clinical trials with some resistance already having been identified., (Copyright © 2018 The Authors. Published by Elsevier B.V. All rights reserved.)- Published
- 2018
- Full Text
- View/download PDF
20. Susceptibility of Brazilian influenza A(H1N1)pdm09 viruses to neuraminidase inhibitors in the 2014-2016 seasons: Identification of strains bearing mutations associated with reduced inhibition profile.
- Author
-
Matos AR, Resende PC, Miranda MD, Garcia CC, Caetano BC, Lopes JCO, Debur MC, Cury ALF, Vianna LA, Lima MC, Schirmer M, Gubareva L, Hurt AC, Brown DW, and Siqueira MM
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Epidemiological Monitoring, Female, Hemagglutinin Glycoproteins, Influenza Virus genetics, Humans, Infant, Infant, Newborn, Influenza, Human drug therapy, Influenza, Human epidemiology, Male, Middle Aged, Mutation, Neuraminidase genetics, Virus Replication drug effects, Young Adult, Antiviral Agents pharmacology, Drug Resistance, Viral genetics, Enzyme Inhibitors pharmacology, Influenza A Virus, H1N1 Subtype drug effects, Influenza A Virus, H1N1 Subtype genetics, Neuraminidase antagonists & inhibitors
- Abstract
Neuraminidase inhibitors (NAIs) are the main class of antivirals currently used for the treatment of influenza infections. As influenza viruses are constantly evolving, drug-resistance can emerge resulting in reduced effectiveness of treatment. This study evaluated the presence of molecular markers associated with NAI susceptibility in 724 influenza A(H1N1)pdm09 positive samples from Brazilian surveillance system from the 2014-2016 seasons, including 76 isolates tested for oseltamivir (OST) susceptibility and 23 isolates also tested for zanamivir, peramivir and laninamivir susceptibility. We identified the H275Y (n = 3) and I223K (n = 1) NA substitutions, associated with reduced inhibition (RI) by the NAIs. Noteworthy, no epidemiological links were identified among the patients infected with the mutant viruses. Phylogenetic analysis from NA and hemagglutinin genes showed that mutant viruses were not clustered. All mutant virus strains carried the permissive substitutions V241I and N369K, in addition to the N386K, which has been shown to destabilize the NA structure. Functional NA analysis of one virus containing the H275Y mutation confirmed its highly RI profile to OST and peramivir and demonstrated that it had decreased viral replication and NA thermostability compared to the wild type virus. The remaining tested isolates presented normal inhibition profile to the NAIs tested. In conclusion, the overall frequency of influenza A(H1N1)pdm09 viruses bearing mutations associated with NAI RI was 0.6%, similar to what has been observed in recent global studies., (Copyright © 2018 Elsevier B.V. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
21. Selection of multi-drug resistant influenza A and B viruses under zanamivir pressure and their replication fitness in ferrets.
- Author
-
Oh DY, Panozzo J, Vitesnik S, Farrukee R, Piedrafita D, Mosse J, and Hurt AC
- Subjects
- Animals, Antiviral Agents therapeutic use, Disease Susceptibility, Ferrets, Influenza A virus classification, Microbial Sensitivity Tests, Mutation, Orthomyxoviridae Infections drug therapy, Orthomyxoviridae Infections virology, RNA, Viral, Recombination, Genetic, Sequence Analysis, DNA, Zanamivir pharmacology, Zanamivir therapeutic use, Antiviral Agents pharmacology, Drug Resistance, Viral, Genetic Fitness, Influenza A virus drug effects, Influenza A virus physiology, Influenza B virus drug effects, Influenza B virus physiology, Virus Replication drug effects
- Abstract
Background: Intravenous zanamivir has been used to treat patients with severe influenza. Because the majority of cases (including immunocompromised patients) require the drug for an extended period of treatment, there is a higher risk that the virus will develop resistance. Therefore, knowing the possible amino acid substitutions that may arise in recently circulating influenza strains under prolonged zanamivir exposure and their impact on antiviral susceptibility is important., Methods: Influenza A(H1N1)pdm09, A(H3N2) and B virus were serially passaged under increasing zanamivir pressure in vitro. Neuraminidase (NA) mutations that arose were introduced into recombinant viruses and the susceptibility to oseltamivir, zanamivir, peramivir and laninamivir was determined. The replication fitness of the recombinant variants was assessed in the ferret., Results: NA mutations E119D (N1 numbering) and E117D (B numbering) were detected in A(H1N1)pdm09 and B (Victoria-lineage) viruses respectively and were associated with reduced susceptibility to all four NA inhibitors. No NA mutations were detected in the A(H3N2) or B (Yamagata-lineage) viruses. In ferrets, the A(H1N1)pdm09 E119D variant caused a lower degree of morbidity and the mutation was found to be unstable with E119 reverted virus detected 4 days post-infection of ferrets with the variant E119D virus. In contrast, the influenza B E117D variant was genetically stable in ferrets, caused a noticeable level of morbidity but had a significant reduction in replication fitness compared to wild-type virus., Conclusions: The NA mutations E119D in influenza A(H1N1)pdm09 and E117D in influenza B viruses that arose under zanamivir pressure conferred resistance to multiple NA inhibitors but had compromised viral replication in ferrets compared to wild-type virus without antiviral drug pressure.
- Published
- 2018
- Full Text
- View/download PDF
22. The susceptibility of circulating human influenza viruses to tizoxanide, the active metabolite of nitazoxanide.
- Author
-
Tilmanis D, van Baalen C, Oh DY, Rossignol JF, and Hurt AC
- Subjects
- Animals, Antiviral Agents toxicity, Cell Survival drug effects, Dogs, Enzyme Inhibitors pharmacology, Humans, Lethal Dose 50, Madin Darby Canine Kidney Cells, Neuraminidase antagonists & inhibitors, Neutralization Tests, Nitro Compounds, Reproducibility of Results, Sensitivity and Specificity, Thiazoles metabolism, Thiazoles toxicity, Antiviral Agents pharmacology, Drug Resistance, Viral drug effects, Influenza A Virus, H1N1 Subtype drug effects, Influenza A Virus, H3N2 Subtype drug effects, Influenza B virus drug effects, Thiazoles pharmacology
- Abstract
Nitazoxanide is a thiazolide compound that was originally developed as an anti-parasitic agent, but has recently been repurposed for the treatment of influenza virus infections. Thought to exert its anti-influenza activity via the inhibition of hemagglutinin maturation and intracellular trafficking in infected cells, the effectiveness of nitazoxanide in treating patients with non-complicated influenza is currently being assessed in phase III clinical trials. Here, we describe the susceptibility of 210 seasonal influenza viruses to tizoxanide, the active circulating metabolite of nitazoxanide. An optimised cell culture-based focus reduction assay was used to determine the susceptibility of A(H1N1)pdm09, A(H3N2), and influenza B viruses circulating in the southern hemisphere from the period March 2014 to August 2016. Tizoxanide showed potent in vitro antiviral activity against all influenza viruses tested, including neuraminidase inhibitor-resistant viruses, allowing the establishment of a baseline level of susceptibility for each subtype. Median EC
50 values (±IQR) of 0.48 μM (0.33-0.71), 0.62 μM (0.56-0.75), 0.66 μM (0.62-0.69), and 0.60 μM (0.51-0.67) were obtained for A(H1N1)pdm09, A(H3N2), B(Victoria lineage), and B(Yamagata lineage) influenza viruses respectively. There was no significant difference in the median baseline tizoxanide susceptibility for each influenza subtype tested. This is the first report on the susceptibility of circulating viruses to tizoxanide. The focus reduction assay format described is sensitive, robust, and less laborious than traditional cell based antiviral assays, making it highly suitable for the surveillance of tizoxanide susceptibility in circulating seasonal influenza viruses., (Copyright © 2017 The Authors. Published by Elsevier B.V. All rights reserved.)- Published
- 2017
- Full Text
- View/download PDF
23. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015-2016.
- Author
-
Gubareva LV, Besselaar TG, Daniels RS, Fry A, Gregory V, Huang W, Hurt AC, Jorquera PA, Lackenby A, Leang SK, Lo J, Pereyaslov D, Rebelo-de-Andrade H, Siqueira MM, Takashita E, Odagiri T, Wang D, Zhang W, and Meijer A
- Subjects
- Acids, Carbocyclic, Amino Acid Substitution, Antiviral Agents administration & dosage, Antiviral Agents therapeutic use, Cyclopentanes pharmacology, Drug Resistance, Viral genetics, Enzyme Inhibitors administration & dosage, Enzyme Inhibitors therapeutic use, Epidemiological Monitoring, Global Health, Guanidines pharmacology, Humans, Influenza A Virus, H1N1 Subtype enzymology, Influenza A Virus, H1N1 Subtype genetics, Influenza B virus enzymology, Influenza B virus genetics, Influenza, Human drug therapy, Influenza, Human virology, Inhibitory Concentration 50, Microbial Sensitivity Tests, Oseltamivir pharmacology, Pyrans, Seasons, Sialic Acids, World Health Organization, Zanamivir analogs & derivatives, Antiviral Agents pharmacology, Enzyme Inhibitors pharmacology, Influenza A Virus, H1N1 Subtype drug effects, Influenza B virus drug effects, Neuraminidase antagonists & inhibitors
- Abstract
Four World Health Organization (WHO) Collaborating Centres for Reference and Research on Influenza and one WHO Collaborating Centre for the Surveillance, Epidemiology and Control of Influenza (WHO CCs) assessed antiviral susceptibility of 14,330 influenza A and B viruses collected by WHO-recognized National Influenza Centres (NICs) between May 2015 and May 2016. Neuraminidase (NA) inhibition assay was used to determine 50% inhibitory concentration (IC
50 ) data for NA inhibitors (NAIs) oseltamivir, zanamivir, peramivir and laninamivir. Furthermore, NA sequences from 13,484 influenza viruses were retrieved from public sequence databases and screened for amino acid substitutions (AAS) associated with reduced inhibition (RI) or highly reduced inhibition (HRI) by NAIs. Of the viruses tested by WHO CCs 93% were from three WHO regions: Western Pacific, the Americas and Europe. Approximately 0.8% (n = 113) exhibited either RI or HRI by at least one of four NAIs. As in previous seasons, the most common NA AAS was H275Y in A(H1N1)pdm09 viruses, which confers HRI by oseltamivir and peramivir. Two A(H1N1)pdm09 viruses carried a rare NA AAS, S247R, shown in this study to confer RI/HRI by the four NAIs. The overall frequency of A(H1N1)pdm09 viruses containing NA AAS associated with RI/HRI was approximately 1.8% (125/6915), which is slightly higher than in the previous 2014-15 season (0.5%). Three B/Victoria-lineage viruses contained a new AAS, NA H134N, which conferred HRI by zanamivir and laninamivir, and borderline HRI by peramivir. A single B/Victoria-lineage virus harboured NA G104E, which was associated with HRI by all four NAIs. The overall frequency of RI/HRI phenotype among type B viruses was approximately 0.6% (43/7677), which is lower than that in the previous season. Overall, the vast majority (>99%) of the viruses tested by WHO CCs were susceptible to all four NAIs, showing normal inhibition (NI). Hence, NAIs remain the recommended antivirals for treatment of influenza virus infections. Nevertheless, our data indicate that it is prudent to continue drug susceptibility monitoring using both NAI assay and sequence analysis., (Copyright © 2017 The Francis Crick Institute. Published by Elsevier B.V. All rights reserved.)- Published
- 2017
- Full Text
- View/download PDF
24. Influenza antivirals currently in late-phase clinical trial.
- Author
-
Koszalka P, Tilmanis D, and Hurt AC
- Subjects
- Humans, Influenza, Human virology, Orthomyxoviridae drug effects, Orthomyxoviridae physiology, Antiviral Agents administration & dosage, Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Influenza, Human drug therapy
- Abstract
Influenza antiviral drugs are important for the control of influenza, most specifically for the treatment of influenza patients with severe disease following infection with a seasonal influenza virus, a newly emerging influenza strain, or in the event of a pandemic. Many influenza antivirals that are currently under investigation in late-stage clinical trials differ in their mechanism of action compared to drugs currently licensed for the treatment of influenza. Nitazoxanide and DAS181 target components of the host cell and alter the ability of the virus to replicate efficiently, while small molecule drugs such as T705, JNJ63623872 and S-033188 bind to the viral polymerase complex and restrict viral replication. Monoclonal antibodies that are currently in clinical trial for the treatment of influenza most commonly are targeted to the stem region of the haemagglutinin molecule. Early findings from animal models and in vitro studies suggest that many of the new antiviral drugs when tested in combination with oseltamivir have improved effectiveness over monotherapy. Clinical trials assessing both monotherapy and combination therapy are currently under investigation. It is hoped that as new antivirals are licensed, they will improve the standard of care and outcomes for influenza patients with severe disease., (© 2017 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd.)
- Published
- 2017
- Full Text
- View/download PDF
25. Fluorescence-based Neuraminidase Inhibition Assay to Assess the Susceptibility of Influenza Viruses to The Neuraminidase Inhibitor Class of Antivirals.
- Author
-
Leang SK and Hurt AC
- Subjects
- Drug Resistance, Viral, Fluorescence, Hymecromone analogs & derivatives, Hymecromone metabolism, Inhibitory Concentration 50, Orthomyxoviridae metabolism, Oseltamivir pharmacology, Zanamivir pharmacology, Antiviral Agents pharmacology, Enzyme Inhibitors pharmacology, Microbial Sensitivity Tests methods, Neuraminidase antagonists & inhibitors, Orthomyxoviridae drug effects
- Abstract
The neuraminidase (NA) inhibitors are the only class of antivirals approved for the treatment and prophylaxis of influenza that are effective against currently circulating strains. In addition to their use in treating seasonal influenza, the NA inhibitors have been stockpiled by a number of countries for use in the event of a pandemic. It is therefore important to monitor the susceptibility of circulating influenza viruses to this class of antivirals. There are different types of assays that can be used to assess the susceptibility of influenza viruses to the NA inhibitors, but the enzyme inhibition assays using either a fluorescent substrate or a chemiluminescent substrate are the most widely used and recommended. This protocol describes the use of a fluorescence-based assay to assess influenza virus susceptibility to NA inhibitors. The assay is based on the NA enzyme cleaving the 2'-(4-Methylumbelliferyl)-α-D-N-acetylneuraminic acid (MUNANA) substrate to release the fluorescent product 4-methylumbelliferone (4-MU). Therefore, the inhibitory effect of an NA inhibitor on the influenza virus NA is determined based on the concentration of the NA inhibitor that is required to reduce 50% of the NA activity, given as an IC50 value.
- Published
- 2017
- Full Text
- View/download PDF
26. Reducing disease burden in an influenza pandemic by targeted delivery of neuraminidase inhibitors: mathematical models in the Australian context.
- Author
-
Moss R, McCaw JM, Cheng AC, Hurt AC, and McVernon J
- Subjects
- Antiviral Agents therapeutic use, Australia epidemiology, Enzyme Inhibitors therapeutic use, Humans, Influenza, Human drug therapy, Influenza, Human epidemiology, Influenza, Human transmission, Models, Theoretical, Risk Assessment, Antiviral Agents administration & dosage, Cost of Illness, Enzyme Inhibitors administration & dosage, Influenza, Human prevention & control, Neuraminidase antagonists & inhibitors, Pandemics prevention & control
- Abstract
Background: Many nations maintain stockpiles of neuraminidase inhibitor (NAI) antiviral agents for use in influenza pandemics to reduce transmission and mitigate the course of clinical infection. Pandemic preparedness plans include the use of these stockpiles to deliver proportionate responses, informed by emerging evidence of clinical impact. Recent uncertainty about the effectiveness of NAIs has prompted these nations to reconsider the role of NAIs in pandemic response, with implications for pandemic planning and for NAI stockpile size., Methods: We combined a dynamic model of influenza epidemiology with a model of the clinical care pathways in the Australian health care system to identify effective NAI strategies for reducing morbidity and mortality in pandemic events, and the stockpile requirements for these strategies. The models were informed by a 2015 assessment of NAI effectiveness against susceptibility, pathogenicity, and transmission of influenza., Results: Liberal distribution of NAIs for early treatment in outpatient settings yielded the greatest benefits in all of the considered scenarios. Restriction of community-based treatment to risk groups was effective in those groups, but failed to prevent the large proportion of cases arising from lower risk individuals who comprise the majority of the population., Conclusions: These targeted strategies are only effective if they can be deployed within the constraints of existing health care infrastructure. This finding highlights the critical importance of identifying optimal models of care delivery for effective emergency health care response.
- Published
- 2016
- Full Text
- View/download PDF
27. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2014-2015.
- Author
-
Hurt AC, Besselaar TG, Daniels RS, Ermetal B, Fry A, Gubareva L, Huang W, Lackenby A, Lee RT, Lo J, Maurer-Stroh S, Nguyen HT, Pereyaslov D, Rebelo-de-Andrade H, Siqueira MM, Takashita E, Tashiro M, Tilmanis D, Wang D, Zhang W, and Meijer A
- Subjects
- Antiviral Agents therapeutic use, Databases, Factual, Dose-Response Relationship, Drug, Drug Resistance, Viral, Global Health, History, 21st Century, Humans, Influenza A virus classification, Influenza A virus genetics, Influenza, Human drug therapy, Influenza, Human history, Microbial Sensitivity Tests, Mutation, Neuraminidase genetics, Population Surveillance, Viral Proteins genetics, World Health Organization, Antiviral Agents pharmacology, Influenza A virus drug effects, Influenza A virus enzymology, Influenza, Human epidemiology, Influenza, Human virology, Neuraminidase antagonists & inhibitors, Viral Proteins antagonists & inhibitors
- Abstract
The World Health Organization (WHO) Collaborating Centres for Reference and Research on Influenza (WHO CCs) tested 13,312 viruses collected by WHO recognized National Influenza Centres between May 2014 and May 2015 to determine 50% inhibitory concentration (IC50) data for neuraminidase inhibitors (NAIs) oseltamivir, zanamivir, peramivir and laninamivir. Ninety-four per cent of the viruses tested by the WHO CCs were from three WHO regions: Western Pacific, the Americas and Europe. Approximately 0.5% (n = 68) of viruses showed either highly reduced inhibition (HRI) or reduced inhibition (RI) (n = 56) against at least one of the four NAIs. Of the twelve viruses with HRI, six were A(H1N1)pdm09 viruses, three were A(H3N2) viruses and three were B/Yamagata-lineage viruses. The overall frequency of viruses with RI or HRI by the NAIs was lower than that observed in 2013-14 (1.9%), but similar to the 2012-13 period (0.6%). Based on the current analysis, the NAIs remain an appropriate choice for the treatment and prophylaxis of influenza virus infections., (Copyright © 2016 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
28. Debate Regarding Oseltamivir Use for Seasonal and Pandemic Influenza.
- Author
-
Hurt AC and Kelly H
- Subjects
- Clinical Trials as Topic, Disease Management, Humans, Influenza, Human diagnosis, Influenza, Human epidemiology, Practice Guidelines as Topic, Seasons, Severity of Illness Index, Treatment Outcome, Antiviral Agents therapeutic use, Influenza A virus classification, Influenza A virus genetics, Influenza, Human drug therapy, Influenza, Human virology, Oseltamivir therapeutic use
- Abstract
A debate about the market-leading influenza antiviral medication, oseltamivir, which initially focused on treatment for generally mild illness, has been expanded to question the wisdom of stockpiling for use in future influenza pandemics. Although randomized controlled trial evidence confirms that oseltamivir will reduce symptom duration by 17-25 hours among otherwise healthy adolescents and adults with community-managed disease, no randomized controlled trials have examined the effectiveness of oseltamivir against more serious outcomes. Observational studies, although criticized on methodologic grounds, suggest that oseltamivir given early can reduce the risk for death by half among persons hospitalized with confirmed infection caused by influenza A(H1N1)pdm09 and influenza A(H5N1) viruses. However, available randomized controlled trial data may not be able to capture the effect of oseltamivir use among hospitalized patients with severe disease. We assert that data on outpatients with relatively mild disease should not form the basis for policies on the management of more severe disease.
- Published
- 2016
- Full Text
- View/download PDF
29. Evaluation of a dry powder delivery system for laninamivir in a ferret model of influenza infection.
- Author
-
Panozzo J, Oh DY, Margo K, Morton DA, Piedrafita D, Mosse J, and Hurt AC
- Subjects
- Administration, Inhalation, Animals, Disease Models, Animal, Ferrets, Guanidines, Placebos administration & dosage, Pyrans, Sialic Acids, Zanamivir administration & dosage, Antiviral Agents administration & dosage, Drug Carriers administration & dosage, Orthomyxoviridae Infections drug therapy, Powders administration & dosage, Zanamivir analogs & derivatives
- Abstract
Laninamivir is a long-acting antiviral requiring only a single dose for the treatment of influenza infection, making it an attractive alternative to existing neuraminidase inhibitors that require multiple doses over many days. Like zanamivir, laninamivir is administered to patients by inhalation of dry powder. To date, studies investigating the effectiveness of laninamivir or zanamivir in a ferret model of influenza infection have administered the drug in a solubilised form. To better mimic the delivery action of laninamivir in humans, we assessed the applicability of a Dry Powder Insufflator™ (DPI) as a delivery method for laninamivir octanoate (LO) in ferrets to determine the effectiveness of this drug in reducing influenza A and B virus infections. In vitro characterisation of the DPI showed that both the small particle sized LO (0.7-6.0μm diameter) and the large particle sized lactose carrier (20-100μm diameter) were effectively discharged. However, LO delivered to ferrets via the DPI prior to infection with either A(H1N1)pdm09 or B viruses had a limited effect on nasal inflammation, clinical symptoms and viral shedding compared to placebo. Our preliminary findings indicate the feasibility of administering powder drugs into ferrets, but a better understanding of the pharmacokinetics and pharmacodynamics of LO in ferrets following delivery by the DPI is warranted prior to further studies., (Copyright © 2015 Elsevier B.V. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
30. Influenza viruses with B/Yamagata- and B/Victoria-like neuraminidases are differentially affected by mutations that alter antiviral susceptibility.
- Author
-
Farrukee R, Leang SK, Butler J, Lee RT, Maurer-Stroh S, Tilmanis D, Sullivan S, Mosse J, Barr IG, and Hurt AC
- Subjects
- Enzyme Inhibitors pharmacology, Inhibitory Concentration 50, Microbial Sensitivity Tests, Models, Molecular, Mutant Proteins chemistry, Mutant Proteins genetics, Neuraminidase chemistry, Protein Conformation, Antiviral Agents pharmacology, Drug Resistance, Viral, Influenza B virus drug effects, Influenza B virus enzymology, Mutation, Missense, Neuraminidase genetics
- Abstract
Objectives: The burden of disease due to influenza B is often underestimated. Clinical studies have shown that oseltamivir, a widely used neuraminidase inhibitor (NAI) antiviral drug, may have reduced effectiveness against influenza B viruses. Therefore, it is important to study the effect of neuraminidase mutations in influenza B viruses that may further reduce NAI susceptibility, and to determine whether these mutations have the same effect in the two lineages of influenza B viruses that are currently circulating (B/Yamagata-like and B/Victoria-like)., Methods: We characterized the effect of 16 amino acid substitutions across five framework residues and four monomeric interface residues on the susceptibility to four different NAIs (oseltamivir, zanamivir, peramivir and laninamivir)., Results: Framework residue mutations E117A and E117G conferred highly reduced inhibition to three of the four NAIs, but substantially reduced neuraminidase activity, whereas other framework mutations retained a greater level of NA activity. Mutations E105K, P139S and G140R of the monomeric interface were also found to cause highly reduced inhibition, but, interestingly, their effect was substantially greater in a B/Victoria-like neuraminidase than in a B/Yamagata-like neuraminidase, with some susceptibility values being up to 1000-fold different between lineages., Conclusions: The frequency and the effect of key neuraminidase mutations on neuraminidase activity and NAI susceptibility can differ substantially between the two influenza B lineages. Therefore, future surveillance, analysis and interpretation of influenza B virus NAI susceptibility should consider the B lineage of the neuraminidase in the same manner as already occurs for different influenza A neuraminidase subtypes., (© The Author 2015. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2015
- Full Text
- View/download PDF
31. Oseltamivir Prophylaxis Reduces Inflammation and Facilitates Establishment of Cross-Strain Protective T Cell Memory to Influenza Viruses.
- Author
-
Bird NL, Olson MR, Hurt AC, Oshansky CM, Oh DY, Reading PC, Chua BY, Sun Y, Tang L, Handel A, Jackson DC, Turner SJ, Thomas PG, and Kedzierska K
- Subjects
- Adolescent, Adult, Animals, CD4-Positive T-Lymphocytes drug effects, CD4-Positive T-Lymphocytes immunology, CD4-Positive T-Lymphocytes virology, CD8-Positive T-Lymphocytes drug effects, CD8-Positive T-Lymphocytes immunology, CD8-Positive T-Lymphocytes virology, Child, Child, Preschool, Female, Ferrets, Humans, Infant, Inflammation immunology, Inflammation virology, Influenza A Virus, H1N1 Subtype immunology, Influenza, Human immunology, Influenza, Human virology, Male, Mice, Mice, Inbred C57BL, Orthomyxoviridae Infections immunology, Orthomyxoviridae Infections virology, Viral Load drug effects, Young Adult, Antiviral Agents therapeutic use, Inflammation prevention & control, Influenza A Virus, H1N1 Subtype drug effects, Influenza, Human prevention & control, Orthomyxoviridae Infections prevention & control, Oseltamivir therapeutic use
- Abstract
CD8(+) T cells directed against conserved viral regions elicit broad immunity against distinct influenza viruses, promote rapid virus elimination and enhanced host recovery. The influenza neuraminidase inhibitor, oseltamivir, is prescribed for therapy and prophylaxis, although it remains unclear how the drug impacts disease severity and establishment of effector and memory CD8(+) T cell immunity. We dissected the effects of oseltamivir on viral replication, inflammation, acute CD8(+) T cell responses and the establishment of immunological CD8(+) T cell memory. In mice, ferrets and humans, the effect of osteltamivir on viral titre was relatively modest. However, prophylactic oseltamivir treatment in mice markedly reduced morbidity, innate responses, inflammation and, ultimately, the magnitude of effector CD8(+) T cell responses. Importantly, functional memory CD8(+) T cells established during the drug-reduced effector phase were capable of mounting robust recall responses. Moreover, influenza-specific memory CD4(+) T cells could be also recalled after the secondary challenge, while the antibody levels were unaffected. This provides evidence that long-term memory T cells can be generated during an oseltamivir-interrupted infection. The anti-inflammatory effect of oseltamivir was verified in H1N1-infected patients. Thus, in the case of an unpredicted influenza pandemic, while prophylactic oseltamivir treatment can reduce disease severity, the capacity to generate memory CD8(+) T cells specific for the newly emerged virus is uncompromised. This could prove especially important for any new influenza pandemic which often occurs in separate waves.
- Published
- 2015
- Full Text
- View/download PDF
32. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013-2014.
- Author
-
Takashita E, Meijer A, Lackenby A, Gubareva L, Rebelo-de-Andrade H, Besselaar T, Fry A, Gregory V, Leang SK, Huang W, Lo J, Pereyaslov D, Siqueira MM, Wang D, Mak GC, Zhang W, Daniels RS, Hurt AC, and Tashiro M
- Subjects
- Acids, Carbocyclic, Amino Acid Substitution, China epidemiology, Cyclopentanes pharmacology, Disease Outbreaks statistics & numerical data, Drug Resistance, Viral genetics, Europe epidemiology, Guanidines pharmacology, Humans, Influenza A Virus, H1N1 Subtype genetics, Influenza A Virus, H3N2 Subtype genetics, Influenza B virus genetics, Inhibitory Concentration 50, Japan epidemiology, Microbial Sensitivity Tests, Neuraminidase chemistry, Oseltamivir pharmacology, Phylogeny, Pyrans, Sialic Acids, Time Factors, United States epidemiology, World Health Organization, Zanamivir analogs & derivatives, Zanamivir pharmacology, Antiviral Agents pharmacology, Enzyme Inhibitors pharmacology, Influenza A Virus, H1N1 Subtype drug effects, Influenza A Virus, H3N2 Subtype drug effects, Influenza B virus drug effects, Neuraminidase antagonists & inhibitors, Neuraminidase genetics
- Abstract
Four World Health Organization (WHO) Collaborating Centres for Reference and Research on Influenza and one WHO Collaborating Centre for the Surveillance, Epidemiology and Control of Influenza (WHO CCs) tested 10,641 viruses collected by WHO-recognized National Influenza Centres between May 2013 and May 2014 to determine 50% inhibitory concentration (IC50) data for neuraminidase inhibitors (NAIs) oseltamivir, zanamivir, peramivir and laninamivir. In addition, neuraminidase (NA) sequence data, available from the WHO CCs and from sequence databases (n=3206), were screened for amino acid substitutions associated with reduced NAI susceptibility. Ninety-five per cent of the viruses tested by the WHO CCs were from three WHO regions: Western Pacific, the Americas and Europe. Approximately 2% (n=172) showed highly reduced inhibition (HRI) against at least one of the four NAIs, commonly oseltamivir, while 0.3% (n=32) showed reduced inhibition (RI). Those showing HRI were A(H1N1)pdm09 with NA H275Y (n=169), A(H3N2) with NA E119V (n=1), B/Victoria-lineage with NA E117G (n=1) and B/Yamagata-lineage with NA H273Y (n=1); amino acid position numbering is A subtype and B type specific. Although approximately 98% of circulating viruses tested during the 2013-2014 period were sensitive to all four NAIs, a large community cluster of A(H1N1)pdm09 viruses with the NA H275Y substitution from patients with no previous exposure to antivirals was detected in Hokkaido, Japan. Significant numbers of A(H1N1)pdm09 NA H275Y viruses were also detected in China and the United States: phylogenetic analyses showed that the Chinese viruses were similar to those from Japan, while the United States viruses clustered separately from those of the Hokkaido outbreak, indicative of multiple resistance-emergence events. Consequently, global surveillance of influenza antiviral susceptibility should be continued from a public health perspective., (Copyright © 2015 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
33. A novel video tracking method to evaluate the effect of influenza infection and antiviral treatment on ferret activity.
- Author
-
Oh DY, Barr IG, and Hurt AC
- Subjects
- Animals, Antiviral Agents therapeutic use, Female, Influenza A Virus, H1N1 Subtype drug effects, Male, Oseltamivir therapeutic use, Antiviral Agents pharmacology, Behavior, Animal drug effects, Ferrets virology, Influenza A Virus, H1N1 Subtype physiology, Orthomyxoviridae Infections drug therapy, Oseltamivir pharmacology, Video Recording
- Abstract
Ferrets are the preferred animal model to assess influenza virus infection, virulence and transmission as they display similar clinical symptoms and pathogenesis to those of humans. Measures of disease severity in the ferret include weight loss, temperature rise, sneezing, viral shedding and reduced activity. To date, the only available method for activity measurement has been the assignment of an arbitrary score by a 'blind' observer based on pre-defined responsiveness scale. This manual scoring method is subjective and can be prone to bias. In this study, we described a novel video-tracking methodology for determining activity changes in a ferret model of influenza infection. This method eliminates the various limitations of manual scoring, which include the need for a sole 'blind' observer and the requirement to recognise the 'normal' activity of ferrets in order to assign relative activity scores. In ferrets infected with an A(H1N1)pdm09 virus, video-tracking was more sensitive than manual scoring in detecting ferret activity changes. Using this video-tracking method, oseltamivir treatment was found to ameliorate the effect of influenza infection on activity in ferret. Oseltamivir treatment of animals was associated with an improvement in clinical symptoms, including reduced inflammatory responses in the upper respiratory tract, lower body weight loss and a smaller rise in body temperature, despite there being no significant reduction in viral shedding. In summary, this novel video-tracking is an easy-to-use, objective and sensitive methodology for measuring ferret activity.
- Published
- 2015
- Full Text
- View/download PDF
34. Zanamivir-resistant influenza viruses with Q136K or Q136R neuraminidase residue mutations can arise during MDCK cell culture creating challenges for antiviral susceptibility monitoring.
- Author
-
Little K, Leang SK, Butler J, Baas C, Harrower B, Mosse J, Barr IG, and Hurt AC
- Subjects
- Animals, Dogs, Enzyme Inhibitors pharmacology, Female, Humans, Influenza A Virus, H1N1 Subtype genetics, Influenza A Virus, H1N1 Subtype isolation & purification, Influenza A Virus, H3N2 Subtype genetics, Influenza A Virus, H3N2 Subtype isolation & purification, Influenza, Human epidemiology, Madin Darby Canine Kidney Cells drug effects, Microbial Sensitivity Tests, Reverse Transcriptase Polymerase Chain Reaction, Viral Proteins genetics, Antiviral Agents pharmacology, Drug Resistance, Viral genetics, Influenza A Virus, H1N1 Subtype drug effects, Influenza A Virus, H3N2 Subtype drug effects, Neuraminidase genetics, Zanamivir pharmacology
- Abstract
Surveillance of circulating influenza strains for antiviral susceptibility is important to ensure patient treatment guidelines remain appropriate. Influenza A(H3N2) and A(H1N1)pdm09 virus isolates containing mutations at the Q136 residue of the neuraminidase (NA) that conferred reduced susceptibility to the NA inhibitor (NAI) zanamivir were detected during antiviral susceptibility monitoring. Interestingly, the mutations were not detectable in the viruses from respective clinical specimens, only in the cultured isolates. We showed that variant viruses containing the Q136K and Q136R NA mutations were preferentially selected in Madin-Darby canine kidney epithelial (MDCK) cells, but were less well supported in MDCK-SIAT1 cells and embryonated eggs. The effect of Q136K, Q136R, Q136H and Q136L substitutions in NA subtypes N1 and N2 on NAI susceptibility and in vitro viral fitness was assessed. This study highlights the challenges that cell culture derived mutations can pose to the NAI susceptibility analysis and interpretation and reaffirms the need to sequence viruses from respective clinical specimens to avoid misdiagnosis. However, we also demonstrate that NA mutations at residue Q136 can confer reduced zanamivir, peramivir or laninamivir susceptibility, and therefore close monitoring of viruses for mutations at this site from patients being treated with these antivirals is important.
- Published
- 2015
- Full Text
- View/download PDF
35. Overview of the 3rd isirv-Antiviral Group Conference--advances in clinical management.
- Author
-
Hurt AC, Hui DS, Hay A, and Hayden FG
- Subjects
- Communicable Diseases, Emerging, Coronavirus Infections drug therapy, Coronavirus Infections epidemiology, Humans, Immunocompromised Host, Influenza Vaccines, Middle East Respiratory Syndrome Coronavirus, Pandemics, Respiratory Syncytial Virus Infections drug therapy, Respiratory Syncytial Virus Infections epidemiology, Antiviral Agents therapeutic use, Influenza, Human drug therapy, Influenza, Human epidemiology, Influenza, Human prevention & control, Influenza, Human virology, Respiratory Tract Infections drug therapy, Respiratory Tract Infections epidemiology, Respiratory Tract Infections prevention & control, Respiratory Tract Infections virology, Virus Diseases drug therapy, Virus Diseases epidemiology, Virus Diseases virology
- Abstract
This review highlights the main points which emerged from the presentations and discussions at the 3rd isirv-Antiviral Group Conference - advances in clinical management. The conference covered emerging and potentially pandemic influenza viruses and discussed novel/pre-licensure therapeutics and currently approved antivirals and vaccines for the control of influenza. Current data on approved and novel treatments for non-influenza respiratory viruses such as MERS-CoV, respiratory syncytial virus (RSV) and rhinoviruses and the challenges of treating immunocompromised patients with respiratory infections was highlighted., (© 2014 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd.)
- Published
- 2015
- Full Text
- View/download PDF
36. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012-2013.
- Author
-
Meijer A, Rebelo-de-Andrade H, Correia V, Besselaar T, Drager-Dayal R, Fry A, Gregory V, Gubareva L, Kageyama T, Lackenby A, Lo J, Odagiri T, Pereyaslov D, Siqueira MM, Takashita E, Tashiro M, Wang D, Wong S, Zhang W, Daniels RS, and Hurt AC
- Subjects
- Acids, Carbocyclic, Amino Acid Substitution, Cyclopentanes therapeutic use, Enzyme Inhibitors therapeutic use, Guanidines therapeutic use, Humans, Influenza A virus isolation & purification, Neuraminidase genetics, Oseltamivir therapeutic use, Pyrans, Sialic Acids, Zanamivir analogs & derivatives, Zanamivir therapeutic use, Antiviral Agents therapeutic use, Drug Resistance, Viral genetics, Influenza A virus drug effects, Influenza, Human drug therapy, Neuraminidase antagonists & inhibitors
- Abstract
Emergence of influenza viruses with reduced susceptibility to neuraminidase inhibitors (NAIs) is sporadic, often follows exposure to NAIs, but occasionally occurs in the absence of NAI pressure. The emergence and global spread in 2007/2008 of A(H1N1) influenza viruses showing clinical resistance to oseltamivir due to neuraminidase (NA) H275Y substitution, in the absence of drug pressure, warrants continued vigilance and monitoring for similar viruses. Four World Health Organization (WHO) Collaborating Centres for Reference and Research on Influenza and one WHO Collaborating Centre for the Surveillance, Epidemiology and Control of Influenza (WHO CCs) tested 11,387 viruses collected by WHO-recognized National Influenza Centres (NIC) between May 2012 and May 2013 to determine 50% inhibitory concentration (IC50) data for oseltamivir, zanamivir, peramivir and laninamivir. The data were evaluated using normalized IC50 fold-changes rather than raw IC50 data. Nearly 90% of the 11,387 viruses were from three WHO regions: Western Pacific, the Americas and Europe. Only 0.2% (n=27) showed highly reduced inhibition (HRI) against at least one of the four NAIs, usually oseltamivir, while 0.3% (n=39) showed reduced inhibition (RI). NA sequence data, available from the WHO CCs and from sequence databases (n=3661), were screened for amino acid substitutions associated with reduced NAI susceptibility. Those showing HRI were A(H1N1)pdm09 with NA H275Y (n=18), A(H3N2) with NA E119V (n=3) or NA R292K (n=1) and B/Victoria-lineage with NA H273Y (n=2); amino acid position numbering is A subtype and B type specific. Overall, approximately 99% of circulating viruses tested during the 2012-2013 period were sensitive to all four NAIs. Consequently, these drugs remain an appropriate choice for the treatment and prophylaxis of influenza virus infections., (Copyright © 2014 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
37. The epidemiology and spread of drug resistant human influenza viruses.
- Author
-
Hurt AC
- Subjects
- Adamantane pharmacology, Adamantane therapeutic use, Antiviral Agents therapeutic use, Humans, Influenza A Virus, H1N1 Subtype isolation & purification, Influenza A Virus, H1N1 Subtype physiology, Influenza A Virus, H3N2 Subtype isolation & purification, Influenza A Virus, H3N2 Subtype physiology, Influenza, Human drug therapy, Neuraminidase genetics, Oseltamivir pharmacology, Oseltamivir therapeutic use, Viral Proteins genetics, Virulence, Antiviral Agents pharmacology, Drug Resistance, Viral, Influenza A Virus, H1N1 Subtype drug effects, Influenza A Virus, H3N2 Subtype drug effects, Influenza, Human epidemiology, Influenza, Human virology, Mutation, Missense
- Abstract
Significant changes in the circulation of antiviral-resistant influenza viruses have occurred over the last decade. The emergence and continued circulation of adamantane-resistant A(H3N2) and A(H1N1)pdm09 viruses mean that the adamantanes are no longer recommended for use. Resistance to the newer class of drugs, the neuraminidase inhibitors, is typically associated with poorer viral replication and transmission. But 'permissive' mutations, that compensated for impairment of viral function in A(H1N1) viruses during 2007/2008, enabled them to acquire the H275Y NA resistance mutation without fitness loss, resulting in their rapid global spread. Permissive mutations now appear to be present in A(H1N1)pdm09 viruses thereby increasing the risk that oseltamivir-resistant A(H1N1)pdm09 viruses may also spread globally, a concerning scenario given that oseltamivir is the most widely used influenza antiviral., (Copyright © 2014 Elsevier B.V. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
38. Evaluation of oseltamivir prophylaxis regimens for reducing influenza virus infection, transmission and disease severity in a ferret model of household contact.
- Author
-
Oh DY, Lowther S, McCaw JM, Sullivan SG, Leang SK, Haining J, Arkinstall R, Kelso A, Mcvernon J, Barr IG, Middleton D, and Hurt AC
- Subjects
- Animals, Disease Models, Animal, Female, Ferrets, Humans, Influenza, Human transmission, Male, Severity of Illness Index, Viral Load, Virus Shedding, Antiviral Agents administration & dosage, Disease Transmission, Infectious prevention & control, Influenza, Human pathology, Influenza, Human prevention & control, Oseltamivir administration & dosage, Pre-Exposure Prophylaxis methods
- Abstract
Objectives: The emergence of the pandemic influenza A(H1N1)pdm09 virus in 2009 saw a significant increase in the therapeutic and prophylactic use of neuraminidase inhibitors (NAIs) to mitigate the impact of this highly transmissible virus. Prior to the pandemic, many countries stockpiled NAIs and developed pandemic plans for the use of antiviral drugs, based on either treatment of high-risk individuals and/or prophylaxis of contacts. However, to date there has been a lack of in vivo models to test the efficacy of treatment or prophylaxis with NAIs, for influenza-infected individuals or exposed contacts, in a household setting., Methods: A ferret model of household contact was developed to study the efficacy of different prophylaxis regimens in preventing infection in contact ferrets exposed to influenza A(H1N1)pdm09-infected index ferrets., Results: Among the different prophylactic regimens, contact ferrets receiving oseltamivir prophylaxis twice daily showed better outcomes than those receiving oseltamivir once daily. Benefits included a significant delay in the time to secondary infection, lower weight loss and higher activity levels. The treatment of index ferrets at 36 h post-infection did not influence either secondary infection rates or clinical symptoms in exposed contact ferrets. Neither prophylaxis nor treatment prevented infection or reduced the duration of viral shedding, although clinical symptoms did improve in infected animals receiving prophylaxis., Conclusions: Different oseltamivir prophylaxis regimens did not prevent infections, but consistently resulted in a reduction in symptoms in infected ferrets. However, oseltamivir prophylaxis failed to reduce viral titres, which warrants further investigation in humans., (© The Author 2014. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.)
- Published
- 2014
- Full Text
- View/download PDF
39. Estimating the fitness advantage conferred by permissive neuraminidase mutations in recent oseltamivir-resistant A(H1N1)pdm09 influenza viruses.
- Author
-
Butler J, Hooper KA, Petrie S, Lee R, Maurer-Stroh S, Reh L, Guarnaccia T, Baas C, Xue L, Vitesnik S, Leang SK, McVernon J, Kelso A, Barr IG, McCaw JM, Bloom JD, and Hurt AC
- Subjects
- Amino Acid Substitution, Animals, Dogs, Ferrets, Humans, Influenza, Human drug therapy, Influenza, Human epidemiology, Influenza, Human genetics, Madin Darby Canine Kidney Cells, Neuraminidase antagonists & inhibitors, Viral Proteins antagonists & inhibitors, Antiviral Agents pharmacology, Drug Resistance, Viral genetics, Genetic Fitness, Influenza A Virus, H1N1 Subtype genetics, Mutation, Missense, Neuraminidase genetics, Oseltamivir pharmacology, Viral Proteins genetics
- Abstract
Oseltamivir is relied upon worldwide as the drug of choice for the treatment of human influenza infection. Surveillance for oseltamivir resistance is routinely performed to ensure the ongoing efficacy of oseltamivir against circulating viruses. Since the emergence of the pandemic 2009 A(H1N1) influenza virus (A(H1N1)pdm09), the proportion of A(H1N1)pdm09 viruses that are oseltamivir resistant (OR) has generally been low. However, a cluster of OR A(H1N1)pdm09 viruses, encoding the neuraminidase (NA) H275Y oseltamivir resistance mutation, was detected in Australia in 2011 amongst community patients that had not been treated with oseltamivir. Here we combine a competitive mixtures ferret model of influenza infection with a mathematical model to assess the fitness, both within and between hosts, of recent OR A(H1N1)pdm09 viruses. In conjunction with data from in vitro analyses of NA expression and activity we demonstrate that contemporary A(H1N1)pdm09 viruses are now more capable of acquiring H275Y without compromising their fitness, than earlier A(H1N1)pdm09 viruses circulating in 2009. Furthermore, using reverse engineered viruses we demonstrate that a pair of permissive secondary NA mutations, V241I and N369K, confers robust fitness on recent H275Y A(H1N1)pdm09 viruses, which correlated with enhanced surface expression and enzymatic activity of the A(H1N1)pdm09 NA protein. These permissive mutations first emerged in 2010 and are now present in almost all circulating A(H1N1)pdm09 viruses. Our findings suggest that recent A(H1N1)pdm09 viruses are now more permissive to the acquisition of H275Y than earlier A(H1N1)pdm09 viruses, increasing the risk that OR A(H1N1)pdm09 will emerge and spread worldwide.
- Published
- 2014
- Full Text
- View/download PDF
40. Peramivir and laninamivir susceptibility of circulating influenza A and B viruses.
- Author
-
Leang SK, Kwok S, Sullivan SG, Maurer-Stroh S, Kelso A, Barr IG, and Hurt AC
- Subjects
- Acids, Carbocyclic, Africa, Asia, Humans, Influenza A virus isolation & purification, Influenza B virus isolation & purification, Influenza, Human virology, Japan, Microbial Sensitivity Tests, Mutation, Missense, Neuraminidase antagonists & inhibitors, Neuraminidase genetics, Oceania, Pyrans, Sialic Acids, Viral Proteins antagonists & inhibitors, Viral Proteins genetics, Zanamivir pharmacology, Antiviral Agents pharmacology, Cyclopentanes pharmacology, Guanidines pharmacology, Influenza A virus drug effects, Influenza B virus drug effects, Zanamivir analogs & derivatives
- Abstract
Influenza viruses collected from regions of Asia, Africa and Oceania between 2009 and 2012 were tested for their susceptibility to two new neuraminidase inhibitors, peramivir and laninamivir. All viruses tested had normal laninamivir inhibition. However, 3·2% (19/599) of A(H1N1)pdm09 viruses had highly reduced peramivir inhibition (due to H275Y NA mutation) and <1% (6/1238) of influenza B viruses had reduced or highly reduced peramivir inhibition, with single occurrence of variants containing I221T, A245T, K360E, A395E, D432G and a combined G145R+Y142H mutation. These data demonstrate that despite an increase in H275Y variants in 2011, there was no marked change in the frequency of peramivir- or laninamivir-resistant variants following the market release of the drugs in Japan in 2010.
- Published
- 2014
- Full Text
- View/download PDF
41. Second isirv antiviral group conference: overview.
- Author
-
Hurt AC, Ison MG, Hayden FG, and Hay AJ
- Subjects
- Drug Resistance, Viral, Humans, Influenza A Virus, H1N1 Subtype pathogenicity, Influenza A Virus, H1N1 Subtype physiology, Influenza, Human diagnosis, Influenza, Human immunology, Influenza, Human virology, Antiviral Agents pharmacology, Influenza A Virus, H1N1 Subtype drug effects, Influenza, Human drug therapy
- Published
- 2013
- Full Text
- View/download PDF
42. Progressive emergence of an oseltamivir-resistant A(H3N2) virus over two courses of oseltamivir treatment in an immunocompromised paediatric patient.
- Author
-
Hurt AC, Leang SK, Tiedemann K, Butler J, Mechinaud F, Kelso A, Downie P, and Barr IG
- Subjects
- Antiviral Agents pharmacology, Child, Preschool, Humans, Immunocompromised Host, Influenza A Virus, H3N2 Subtype genetics, Male, Mutation, Missense, Oseltamivir pharmacology, Selection, Genetic, Antiviral Agents therapeutic use, Drug Resistance, Viral, Influenza A Virus, H3N2 Subtype drug effects, Influenza A Virus, H3N2 Subtype isolation & purification, Influenza, Human drug therapy, Influenza, Human virology, Oseltamivir therapeutic use
- Abstract
A minor viral population of oseltamivir-resistant A(H3N2) viruses (E119V neuraminidase mutation) was selected and maintained in a continually infected immunocompromised child following initial oseltamivir treatment. A subsequent course of oseltamivir given 7 weeks later rapidly selected for the E119V variant resulting in a near-pure population of the resistant virus. The study highlights the challenges of oseltamivir treatment of immunocompromised patients that are continually shedding virus and demonstrates the ability of the E119V oseltamivir-resistant virus to be maintained for prolonged periods even in the absence of drug-selective pressure., (© 2013 John Wiley & Sons Ltd.)
- Published
- 2013
- Full Text
- View/download PDF
43. Review of the clinical effectiveness of the neuraminidase inhibitors against influenza B viruses.
- Author
-
Farrukee R, Mosse J, and Hurt AC
- Subjects
- Antiviral Agents chemistry, Antiviral Agents pharmacology, Guanidines, Humans, Influenza A virus drug effects, Influenza, Human prevention & control, Microbial Sensitivity Tests, Oseltamivir chemistry, Oseltamivir pharmacology, Oseltamivir therapeutic use, Pyrans, Sialic Acids, Zanamivir analogs & derivatives, Zanamivir chemistry, Zanamivir pharmacology, Zanamivir therapeutic use, Antiviral Agents therapeutic use, Influenza B virus drug effects, Influenza, Human drug therapy, Neuraminidase antagonists & inhibitors
- Abstract
Influenza A and B viruses cause significant morbidity and mortality worldwide each year. The neuraminidase inhibitors (NAIs) are the most commonly used class of influenza antiviral drugs for the treatment of infected patients. In vitro studies have shown that influenza B viruses are significantly less susceptible to oseltamivir and other neuraminidase inhibitors compared with influenza A viruses. Following analysis of published clinical studies, we show that oseltamivir does appear to have lower effectiveness in patients infected with influenza B virus compared with influenza A infected patients, but due to insufficient studies on zanamivir, laninamivir or peramivir, it was not possible to conclude the relative effectiveness of these drugs against influenza A virus compared with B virus.
- Published
- 2013
- Full Text
- View/download PDF
44. Influenza antiviral resistance in the Asia-Pacific region during 2011.
- Author
-
Leang SK, Deng YM, Shaw R, Caldwell N, Iannello P, Komadina N, Buchy P, Chittaganpitch M, Dwyer DE, Fagan P, Gourinat AC, Hammill F, Horwood PF, Huang QS, Ip PK, Jennings L, Kesson A, Kok T, Kool JL, Levy A, Lin C, Lindsay K, Osman O, Papadakis G, Rahnamal F, Rawlinson W, Redden C, Ridgway J, Sam IC, Svobodova S, Tandoc A, Wickramasinghe G, Williamson J, Wilson N, Yusof MA, Kelso A, Barr IG, and Hurt AC
- Subjects
- Asia, Humans, Influenza A virus isolation & purification, Influenza B virus isolation & purification, Inhibitory Concentration 50, Microbial Sensitivity Tests, Pacific Islands, Antiviral Agents pharmacology, Influenza A virus drug effects, Influenza B virus drug effects, Influenza, Human virology
- Abstract
Despite greater than 99% of influenza A viruses circulating in the Asia-Pacific region being resistant to the adamantane antiviral drugs in 2011, the large majority of influenza A (>97%) and B strains (∼99%) remained susceptible to the neuraminidase inhibitors oseltamivir and zanamivir. However, compared to the first year of the 2009 pandemic, cases of oseltamivir-resistant A(H1N1)pdm09 viruses with the H275Y neuraminidase mutation increased in 2011, primarily due to an outbreak of oseltamivir-resistant viruses that occurred in Newcastle, as reported in Hurt et al. (2011c, 2012a), where the majority of the resistant viruses were from community patients not being treated with oseltamivir. A small number of influenza B viruses with reduced oseltamivir or zanamivir susceptibility were also detected. The increased detection of neuraminidase inhibitor resistant strains circulating in the community and the detection of novel variants with reduced susceptibility are reminders that monitoring of influenza viruses is important to ensure that antiviral treatment guidelines remain appropriate., (Copyright © 2012. Published by Elsevier B.V.)
- Published
- 2013
- Full Text
- View/download PDF
45. Influenza antivirals and resistance: the next 10 years?
- Author
-
Hurt AC, Butler J, Kelso A, and Barr IG
- Subjects
- Drug Discovery, Humans, Influenza, Human virology, Neuraminidase antagonists & inhibitors, Antiviral Agents therapeutic use, Drug Resistance, Viral, Influenza, Human drug therapy
- Published
- 2012
- Full Text
- View/download PDF
46. The ongoing battle against influenza: Drug-resistant influenza viruses: why fitness matters.
- Author
-
Kelso A and Hurt AC
- Subjects
- Antiviral Agents therapeutic use, Genetic Fitness, Humans, Influenza A Virus, H1N1 Subtype pathogenicity, Influenza, Human virology, Oseltamivir pharmacology, Oseltamivir therapeutic use, Zanamivir pharmacology, Zanamivir therapeutic use, Antiviral Agents pharmacology, Drug Resistance, Viral genetics, Influenza A Virus, H1N1 Subtype drug effects, Influenza A Virus, H1N1 Subtype genetics, Influenza, Human drug therapy
- Published
- 2012
- Full Text
- View/download PDF
47. Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives.
- Author
-
Hurt AC, Chotpitayasunondh T, Cox NJ, Daniels R, Fry AM, Gubareva LV, Hayden FG, Hui DS, Hungnes O, Lackenby A, Lim W, Meijer A, Penn C, Tashiro M, Uyeki TM, and Zambon M
- Subjects
- Humans, Influenza, Human diagnosis, Influenza, Human epidemiology, Oseltamivir therapeutic use, Time Factors, Antiviral Agents therapeutic use, Drug Resistance, Viral, Influenza A Virus, H1N1 Subtype, Influenza, Human drug therapy, Pandemics, Public Health
- Abstract
Influenza A H1N1 2009 virus caused the first pandemic in an era when neuraminidase inhibitor antiviral drugs were available in many countries. The experiences of detecting and responding to resistance during the pandemic provided important lessons for public health, laboratory testing, and clinical management. We propose recommendations for antiviral susceptibility testing, reporting results, and management of patients infected with 2009 pandemic influenza A H1N1. Sustained global monitoring for antiviral resistance among circulating influenza viruses is crucial to inform public health and clinical recommendations for antiviral use, especially since community spread of oseltamivir-resistant A H1N1 2009 virus remains a concern. Further studies are needed to better understand influenza management in specific patient groups, such as severely immunocompromised hosts, including optimisation of antiviral treatment, rapid sample testing, and timely reporting of susceptibility results., (Copyright © 2012 Elsevier Ltd. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
48. The detection of oseltamivir-resistant pandemic influenza A/H1N1 2009 viruses using a real-time RT-PCR assay.
- Author
-
Chidlow GR, Harnett GB, Williams SH, Tempone SS, Speers DJ, Hurt AC, Deng YM, and Smith DW
- Subjects
- Amino Acid Substitution genetics, Humans, Microbial Sensitivity Tests methods, Mutation, Missense, Neuraminidase genetics, Point Mutation, RNA, Viral genetics, Viral Proteins genetics, Antiviral Agents pharmacology, Drug Resistance, Viral, Influenza A Virus, H1N1 Subtype drug effects, Influenza, Human virology, Oseltamivir pharmacology, Reverse Transcriptase Polymerase Chain Reaction methods
- Abstract
A real-time reverse transcription PCR (rRT-PCR) assay was designed and evaluated for the detection of the point mutation in the influenza A N1 neuraminidase gene that results in a tyrosine to histidine substitution at amino acid position 275 (H275Y) causing resistance to oseltamivir, an antiviral neuraminidase inhibitor. The rRT-PCR assays detected the presence or absence of the H275Y mutation in 387/388 (99.7%) of clinical samples containing the pandemic influenza A/H1N1 2009 virus. The H275Y mutation was not detected in any of the community patient samples (0/132) but was detected in four hospitalized patients who had been treated with oseltamivir for several days. The sensitive rRT-PCR assays may be performed directly on patient specimens, can detect resistant virus at low levels, and therefore may provide early warning of developing resistance within individual patients or the wider population., (Crown Copyright (c) 2010. Published by Elsevier B.V. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
49. Assessing the viral fitness of oseltamivir-resistant influenza viruses in ferrets, using a competitive-mixtures model.
- Author
-
Hurt AC, Nor'e SS, McCaw JM, Fryer HR, Mosse J, McLean AR, and Barr IG
- Subjects
- Animals, Ferrets, Humans, Influenza A Virus, H1N1 Subtype drug effects, Influenza A Virus, H1N1 Subtype growth & development, Influenza A Virus, H1N1 Subtype isolation & purification, Influenza A Virus, H3N2 Subtype drug effects, Influenza A Virus, H3N2 Subtype growth & development, Influenza A Virus, H3N2 Subtype isolation & purification, Influenza, Human virology, Models, Theoretical, Molecular Sequence Data, Mutation, Missense, Neuraminidase genetics, RNA, Viral genetics, Sequence Analysis, DNA, Viral Proteins genetics, Antiviral Agents pharmacology, Drug Resistance, Viral, Influenza A Virus, H1N1 Subtype physiology, Influenza A Virus, H3N2 Subtype physiology, Oseltamivir pharmacology, Virus Replication
- Abstract
To determine the relative fitness of oseltamivir-resistant strains compared to susceptible wild-type viruses, we combined mathematical modeling and statistical techniques with a novel in vivo "competitive-mixtures" experimental model. Ferrets were coinfected with either pure populations (100% susceptible wild-type or 100% oseltamivir-resistant mutant virus) or mixed populations of wild-type and oseltamivir-resistant influenza viruses (80%:20%, 50%:50%, and 20%:80%) at equivalent infectivity titers, and the changes in the relative proportions of those two viruses were monitored over the course of the infection during within-host and over host-to-host transmission events in a ferret contact model. Coinfection of ferrets with mixtures of an oseltamivir-resistant R292K mutant A(H3N2) virus and a R292 oseltamivir-susceptible wild-type virus demonstrated that the R292K mutant virus was rapidly outgrown by the R292 wild-type virus in artificially infected donor ferrets and did not transmit to any of the recipient ferrets. The competitive-mixtures model was also used to investigate the fitness of the seasonal A(H1N1) oseltamivir-resistant H274Y mutant and showed that within infected ferrets the H274Y mutant virus was marginally outgrown by the wild-type strain but demonstrated equivalent transmissibility between ferrets. This novel in vivo experimental method and accompanying mathematical analysis provide greater insight into the relative fitness, both within the host and between hosts, of two different influenza virus strains compared to more traditional methods that infect ferrets with only pure populations of viruses. Our statistical inferences are essential for the development of the next generation of mathematical models of the emergence and spread of oseltamivir-resistant influenza in human populations.
- Published
- 2010
- Full Text
- View/download PDF
50. Assessing the development of oseltamivir and zanamivir resistance in A(H5N1) influenza viruses using a ferret model.
- Author
-
Hurt AC, Lowther S, Middleton D, and Barr IG
- Subjects
- Amino Acid Substitution genetics, Animals, DNA Mutational Analysis, Disease Models, Animal, Female, Ferrets, Humans, Inhibitory Concentration 50, Microbial Sensitivity Tests, Mutation, Missense, Neuraminidase genetics, Viral Proteins genetics, Antiviral Agents pharmacology, Drug Resistance, Viral, Influenza A Virus, H5N1 Subtype drug effects, Orthomyxoviridae Infections drug therapy, Orthomyxoviridae Infections virology, Oseltamivir pharmacology, Zanamivir pharmacology
- Abstract
Using an in vivo ferret model, we investigated the development of resistance to oseltamivir and zanamivir for two different influenza A(H5N1) viruses (A/Vietnam/1203/2004, haemagglutinin phylogenetic clade 1, and A/Chicken/Laos/26/2006, haemagglutinin phylogenetic clade 2.3) by treating the animals with doses equivalent either to the recommended human treatment dose or a range of sub-optimal drug doses. No resistance was observed in oseltamivir-treated ferrets, but analysis of nasal washes from zanamivir-treated ferrets infected with influenza A/Vietnam/1203/2004 revealed one viral isolate (from a ferret receiving the highest dose of zanamivir, 1.0mg/kg twice daily) with a zanamivir IC(50) that was 350-fold higher than the other isolates tested. The same virus also demonstrated a 26-fold increase in oseltamivir IC(50). The isolate with reduced susceptibility was taken from a ferret 8 days post-infection that was being treated with the recommended human zanamivir dose. Sequence analysis of the resistant virus revealed a glutamine (Q) to leucine (L) mutation at residue 136 of the neuraminidase. This is the first report of this mutation being associated with neuraminidase inhibitor susceptibility and one of the few reported mutations that confer zanamivir resistance, and as such should be closely monitored in influenza A(H5N1) and other N1 viruses in the future. Further animal studies and human clinical trials are necessary to optimize neuraminidase inhibitor dosing strategies for the treatment of influenza A(H5N1) infections., (2010 Elsevier B.V. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.